The Canadian Hemophilia Society (CHS) is proud to put out its call for applications for its research programs for the 2021-2022 grant period. The deadline to submit applications for all the programs is November 16, 2020. The eligibility criteria and conditions for all our research programs have been revised and updated. Of note, eligibility has been expanded as follows:
Ø Dream of a Cure: the program is no longer limited to hemophilia A & B-related projects so that projects focusing on von Willebrand disease, rare factor deficiencies, platelet function disorders (and platelet pathophysiology) and other congenital and acquired bleeding disorders can be supported;
Ø Dream of a Cure Studentships in Inherited Bleeding Disorders Research: similarly to our basic scientific research program, the studentships are no longer limited to hemophilia-related projects but include all inherited bleeding disorders. Furthermore, science students in any year of an undergraduate program can apply in addition to medical students in any year of training;
Ø CHS/Pfizer Care Until Cure Research Program: the areas of interest to which investigators are encouraged to submit proposals has been expanded to include mild hemophilia A and B and Factor Utilization & Cost-effectiveness; all projects included but not limited to the list will be considered;
Ø CHS/Novo Nordisk Psychosocial Research Programme: applications from Social Workers, Nurses, or Physiotherapists with professional experience in a hemophilia treatment centre (or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders) or persons interested in the field of inherited bleeding disorders will be considered. Students in a PhD program in one of the allied health disciplines may also apply. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. Professional experience in a hemophilia treatment centre is desirable but not required.
Ø CHS/Bayer ADVANCE Canada Research Program: applicant must be a physician or Ph.D. with professional experience in a hemophilia treatment centre (HTC) or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. The proposed research must have relevance to current practice in bleeding disorders care and may incorporate a broad spectrum of quantitative and qualitative research methods addressing professional practice with individuals, families, groups and communities, organizational issues, public health, and education.The research studies should aim to provide better data and tools to help the treaters assist patients in successful ageing.
DREAM OF A CURE
Through funds provided by the Hemophilia Research Million Dollar Club and the CHS, the CHS provides basic scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, platelet function disorders and ultimately, finding a cure.
Dream of a Cure, the CHS Research Program and the 2021 Dream of a Cure Summer Studentships in Inherited Bleeding Disorders Research application forms as well as the general criteria and conditions are available by accessing the CHS Web site at https://www.hemophilia.ca/chs-dream-of-a-cure-research-program/. For Dream of a Cure, individual grants will be awarded to researchers for one to two years for amounts up to $75,000 per year while support will be offered to interested Canadian medical or science students for up to 4 months for a maximum stipend of $6,000 per student.
CHS / PFIZER CARE UNTIL CURE RESEARCH PROGRAM
You will find at https://www.hemophilia.ca/the-chspfizer-care-until-cure-research-program/ the information for the CHS/Pfizer Care until Cure Research Program offered by the CHS in collaboration with Pfizer Canada. This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders. Grants for one to two years with a maximum of $75,000 per year will be awarded for clinical research, including outcome evaluation, in fields relevant to improving the health and the quality of life for persons with Hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C infection, and carriers of an inherited bleeding disorder.
CHS/NOVO NORDISK CANADA PSYCHOSOCIAL RESEARCH PROGRAMME
The CHS/Novo Nordisk Canada Psychosocial Research Program was created to engage hemophilia program professionals/graduate students from the allied health disciplines (ie. Nursing, Physiotherapy & Social Work) in research activities addressed to understanding the psychosocial impact of hemophilia and other inherited bleeding disorders and to improve the quality of life of persons and families whose lives are affected by these disorders.
The primary intent of this program is to offer one or two $20,000 research grants, to a maximum of $40,000 for one year.
Depending upon the number and quality of applications, funding for more than two research grant could be offered within the allotted total budget stated above.
The major portion of each grant would be to cover the research time for the successful candidate(s), including the time for research assistants. A small amount can be devoted to project expenses.
Collaboration with multidisciplinary care providers and/or between two or more hemophilia centres is accepted and encouraged. Collaboration efforts may include, for example, social work, physical therapy and genetics. It thus may be possible for a hemophilia centre team to jointly submit a cooperative research project. Additionally, inter-regional applications will be considered.
Applications and Deadline:
A letter of intent should be submitted to the Canadian Hemophilia Society by November 16, 2020. The letter, with a maximum of two pages, should identify the researcher, the organization and include a summary description of the intended area of research.
The CHS Peer Review Committee will invite a limited number of candidates to submit a more detailed proposal by January 18, 2021 in order to make a final selection. Grants will be offered for a one-year period to begin in April 2021.
More detailed information is available by accessing the CHS Web site at https://www.hemophilia.ca/the-chsnovo-nordisk-psychosocial-research-program/
The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program
The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.
The research program will support studies that aim to:
• Identify and provide insight into key issues associated with the ageing hemophilia population
• Identify how management of age-related co-morbidities should be adapted to those with hemophilia
• Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia
The primary intent of this program is to offer one or two $30,000 research grants, to a maximum of $60,000 for one year.
Applications and Deadline:
All completed application forms and support documents must arrive at the National Office of the Canadian Hemophilia Society on or before November 16, 2020.
Additional information, the eligibility criteria and conditions for the research program as well as the application form can be found on our website at this link:
Please feel free to distribute this information to others who may be interested in applying. The research must be conducted in Canada by researchers affiliated with Canadian universities and not-for-profit-related organizations.
If you require further information, please do not hesitate to contact Mr. Michel Long at the CHS National Office at 1-800-668-2686 or by e-mail at firstname.lastname@example.org.
National Program Manager | Gestionnaire national des programmes
Canadian Hemophilia Society | Société canadienne de l'hémophilie
301-666, rue Sherbrooke Ouest, Montréal (QC) H3A 1E7
' 514 848-0503, # 225 | 1 800 668-2686